MALAGOLA, MICHELE
MALAGOLA, MICHELE
Alma Mater Studiorum Universita' di Bologna
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia.
2005-01-01 PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M.
Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation.
2004-01-01 PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BIANCHINI M; VIGNA E; BOSI C; GAITANI S; VISANI G; BACCARANI M.
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR)
2016-01-01 Bernardi Simona, Andrea Di Palma, Federica Cattina, Simone Perucca, Michele Malagola, Mario Tiribelli, Erika Codarin, Maria Teresa Bochicchio, Giuseppina Ruggeri, Luca Franceschini, Valeria Cancelli, Fausto Castagnetti, Simona Soverini, Miriam Fogli, Claudia Venturi, Serena Lavorgna, Chiara Pagani, Cristina Skert, Camilla Zanaglio, Alessandro Turra, Nicola Polverelli, Luigi Caimi, Giuseppe Rossi, Maria Teresa Voso, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Domenico Russo
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts
2004-01-01 Martinelli, Giovanni; Ottaviani, Emanuela; Buonamici, Silvia; Isidori, Alessandro; Borsaru, Gabriela; Visani, Giuseppe; Piccaluga, Pier Paolo; Malagola, Michele; Testoni, Nicoletta; Rondoni, Michela; Nucifora, Giuseppina; Tura, Sante; Baccarani, Michele
Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era
2012-01-01 SOVERINI S.; GNANI A.; CATERINA DE BENEDITTIS C.; IACOBUCCI I.; VENTURI C.; PAPAYANNIDIS C.; LUPPI M.; MERANTE S.; MALAGOLA M.; RUSSO D.; TIRIBELLI M.; SALVUCCI M.; VITALE A.; ELIA L.; VIGNETTI M.; FOÀ R.; BACCARANI M.; MARTINELLI G.
Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients.
2007-01-01 Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E; Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Fili C; Baccarani M; Russo D.
Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine
2006-01-01 Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; Isidori A; Sparaventi G; Leoni P.
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs)
2015-01-01 Simona Bernardi, Andrea Di Palma, Mario Tiribelli, Erika Codarin, Giuseppina Ruggeri, Maria Teresa Bochicchio, Michele Malagola, Federica Cattina, Simone Perucca, Valeria Cancelli, Crisitina Skert, Gianantonio Rosti, Fausto Castagnetti, Luigi Caimi, Giuseppe Rossi, Giovanni Martinelli, Domenico Russo
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia
2004-01-01 PICCALUGA PP; MALAGOLA M; RONDONI M; AMABILE M; PAOLINI S; SOVERINI S; GAITANI S; VISANI G; BACCARANI M.; MARTINELLI G
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia.
2013-01-01 Russo D; Martinelli G; Malagola M; Skert C; Soverini S; Iacobucci I; De Vivo A; Testoni N; Castagnetti F; Gugliotta G; Turri D; Bergamaschi M; Pregno P; Pungolino E; Stagno F; Breccia M; Martino B; Intermesoli T; Fava C; Abruzzese E; Tiribelli M; Bigazzi C; Cesana BM; Rosti G; Baccarani M.
First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients.
2004-01-01 PICCALUGA PP; MARTINELLI G; RONDONI M; MALAGOLA M; GAITANI S; VISANI G; BACCARANI M.
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study
2011-01-01 Mariachiara Abbenante, Cristina Papayannidis, Ilaria Iacobucci, Anna Candoni, Stefania Paolini, Michele Malagola, Ottaviani Emanuela, Annalisa Lonetti, Antonio Curti, Sarah Parisi, Nicoletta Testoni, Barbara Lama, Michele Baccarani, Giovanni Martinelli
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas
2004-01-01 PICCALUGA PP; MARTINELLI G.; RONDONI M; MALAGOLA M; GAITANI S; ISIDORI A; BONINI A; GUGLIOTTA L; LUPPI M; MORSELLI M; SPARAVENTI G; VISANI G; BACCARANI M.
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia
2015-01-01 Papayannidis, Cristina; Candoni, Anna; Malagola, Michele; Marconi, Giovanni; Manfrini, Marco; Simonetti, Giorgia; Zuffa, Elisa; Abbenante, Mariachiara; Parisi, Sarah; Paolini, Stefania; Sartor, Chiara; Franchini, Eugenia; Ottaviani, Emanuela; Venturi, Claudia; Fontana, MARIA CHIARA; Padella, Antonella; Guadagnuolo, Viviana; Bochicchio, MARIA TERESA; Ferrari, Anna; Soverini, Simona; Testoni, Nicoletta; Baldazzi, Carmen; Fanin, Renato; Russo, Domenico; Cavo, Michele; Martinelli, Giovanni
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years
2008-01-01 Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R.
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia
2004-01-01 PICCALUGA PP; LUATTI S; ASCANI S; BIANCHINI M; MALAGOLA M; RONDONI M; GAITANI S; TESTONI N.; PILERI SA; BACCARANI M; MARTINELLI G; VISANI G
Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.
2004-01-01 MARTINELLI G; MALAGOLA M; OTTAVIANI E; ROSTI G; TRABACCHI E; BACCARANI M.
Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
2005-01-01 Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; Basi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M.
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases
2008-01-01 Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D.
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE
2012-01-01 D Russo; G Martinelli; M Malagola; V Cancelli; S Zedda; C Skert; S Soverini; I Iacobucci; D Turri; S Mirto; M Gobbi; I Pierri1; U Vitolo; P Pregno; M Fogli; N Testoni; A De vivo; F Castagnetti; E Morra; E Pungolino; F Di Raimondo; F Stagno; G Alimena; M Breccia; F Nobile; B Martino; A Rambaldi; T Intermesoli; G Saglio; G Rege Cambrin; G Visani; G Nicolini; P De Fabritiis; E Abruzzese; R Fanin; M Tiribelli ; P Galieni; C Bigazzi; G Specchia; E Angelucci; E Usala; C Musolino; S Ruso; L Gaidano; M Lunghi; F Lauria; M Bocchia; F Rodeghiero; A D’Emilio; A Bosi; V Santini; G Quarta; M Girasoli; G Fioritoni; R Di Lorenzo; B Cesana; G Rosti; M Baccarani.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia. | PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BONIFAZI F; BANDINI G; VISANI G; BACCARANI M. | 2005-01-01 | LEUKEMIA | - | 1.01 Articolo in rivista | - |
| Anti-leukemic and anti-GVHD effects of campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. | PICCALUGA PP; MARTINELLI G; MALAGOLA M; RONDONI M; BIANCHINI M; VIGNA E; BOSI C; GAITANI S; VISAN...I G; BACCARANI M. | 2004-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) | Bernardi Simona, Andrea Di Palma, Federica Cattina, Simone Perucca, Michele Malagola, Mario Tirib...elli, Erika Codarin, Maria Teresa Bochicchio, Giuseppina Ruggeri, Luca Franceschini, Valeria Cancelli, Fausto Castagnetti, Simona Soverini, Miriam Fogli, Claudia Venturi, Serena Lavorgna, Chiara Pagani, Cristina Skert, Camilla Zanaglio, Alessandro Turra, Nicola Polverelli, Luigi Caimi, Giuseppe Rossi, Maria Teresa Voso, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, Domenico Russo | 2016-01-01 | BLOOD | - | 1.06 Abstract in rivista | - |
| Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts | Martinelli, Giovanni; Ottaviani, Emanuela; Buonamici, Silvia; Isidori, Alessandro; Borsaru, Gabri...ela; Visani, Giuseppe; Piccaluga, Pier Paolo; Malagola, Michele; Testoni, Nicoletta; Rondoni, Michela; Nucifora, Giuseppina; Tura, Sante; Baccarani, Michele | 2004-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | 1221.full.pdf |
| Bcr-Abl kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the 2nd-generation TKI era | SOVERINI S.; GNANI A.; CATERINA DE BENEDITTIS C.; IACOBUCCI I.; VENTURI C.; PAPAYANNIDIS C.; LUPP...I M.; MERANTE S.; MALAGOLA M.; RUSSO D.; TIRIBELLI M.; SALVUCCI M.; VITALE A.; ELIA L.; VIGNETTI M.; FOÀ R.; BACCARANI M.; MARTINELLI G. | 2012-01-01 | JOURNAL OF CLINICAL ONCOLOGY | - | 4.02 Riassunto (Abstract) | - |
| Case-control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. |
Malagola M; Damiani D; Martinelli G; Michelutti A; Cesana B; Vivo AD; Piccaluga PP; Ottaviani E;... Candoni A; Geromin A; Tiribelli M; Fanin R; Testoni N; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Fili C; Baccarani M; Russo D. |
2007-01-01 | BRITISH JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Consolidation therapy for adult acute myeloid leukemia: A systematic analysis according to evidence based medicine | Visani G; Olivieri A; Malagola M; Brunori M; Piccaluga PP; Capelli D; Pomponio G; Martinelli G; I...sidori A; Sparaventi G; Leoni P. | 2006-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) | Simona Bernardi, Andrea Di Palma, Mario Tiribelli, Erika Codarin, Giuseppina Ruggeri, Maria Teres...a Bochicchio, Michele Malagola, Federica Cattina, Simone Perucca, Valeria Cancelli, Crisitina Skert, Gianantonio Rosti, Fausto Castagnetti, Luigi Caimi, Giuseppe Rossi, Giovanni Martinelli, Domenico Russo | 2015-01-01 | BLOOD | - | 1.06 Abstract in rivista | - |
| Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia | PICCALUGA PP; MALAGOLA M; RONDONI M; AMABILE M; PAOLINI S; SOVERINI S; GAITANI S; VISANI G; BACCA...RANI M.; MARTINELLI G | 2004-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. | Russo D; Martinelli G; Malagola M; Skert C; Soverini S; Iacobucci I; De Vivo A; Testoni N; Castag...netti F; Gugliotta G; Turri D; Bergamaschi M; Pregno P; Pungolino E; Stagno F; Breccia M; Martino B; Intermesoli T; Fava C; Abruzzese E; Tiribelli M; Bigazzi C; Cesana BM; Rosti G; Baccarani M. | 2013-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. | PICCALUGA PP; MARTINELLI G; RONDONI M; MALAGOLA M; GAITANI S; VISANI G; BACCARANI M. | 2004-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study | Mariachiara Abbenante, Cristina Papayannidis, Ilaria Iacobucci, Anna Candoni, Stefania Paolini, M...ichele Malagola, Ottaviani Emanuela, Annalisa Lonetti, Antonio Curti, Sarah Parisi, Nicoletta Testoni, Barbara Lama, Michele Baccarani, Giovanni Martinelli | 2011-01-01 | CANCER RESEARCH | - | 1.06 Abstract in rivista | - |
| Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas | PICCALUGA PP; MARTINELLI G.; RONDONI M; MALAGOLA M; GAITANI S; ISIDORI A; BONINI A; GUGLIOTTA L; ...LUPPI M; MORSELLI M; SPARAVENTI G; VISANI G; BACCARANI M. | 2004-01-01 | LEUKEMIA & LYMPHOMA | - | 1.01 Articolo in rivista | - |
| Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia | Papayannidis, Cristina; Candoni, Anna; Malagola, Michele; Marconi, Giovanni; Manfrini, Marco; Sim...onetti, Giorgia; Zuffa, Elisa; Abbenante, Mariachiara; Parisi, Sarah; Paolini, Stefania; Sartor, Chiara; Franchini, Eugenia; Ottaviani, Emanuela; Venturi, Claudia; Fontana, MARIA CHIARA; Padella, Antonella; Guadagnuolo, Viviana; Bochicchio, MARIA TERESA; Ferrari, Anna; Soverini, Simona; Testoni, Nicoletta; Baldazzi, Carmen; Fanin, Renato; Russo, Domenico; Cavo, Michele; Martinelli, Giovanni | 2015-01-01 | BLOOD | - | 1.06 Abstract in rivista | - |
| Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years | Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Miche...lutti A; Simeone E; Damiani D; Russo D; Fanin R. | 2008-01-01 | LEUKEMIA RESEARCH | - | 1.01 Articolo in rivista | - |
| Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia | PICCALUGA PP; LUATTI S; ASCANI S; BIANCHINI M; MALAGOLA M; RONDONI M; GAITANI S; TESTONI N.; PILE...RI SA; BACCARANI M; MARTINELLI G; VISANI G | 2004-01-01 | CANCER GENETICS AND CYTOGENETICS | - | 1.01 Articolo in rivista | - |
| Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome. | MARTINELLI G; MALAGOLA M; OTTAVIANI E; ROSTI G; TRABACCHI E; BACCARANI M. | 2004-01-01 | HAEMATOLOGICA | - | 1.01 Articolo in rivista | - |
| Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target? | Malagola M; Martinelli G; Rondoni M; Paolini S; Gaitani S; Arpinati M; Piccaluga PP; Amabile M; B...asi C; Ottaviani E; Candoni A; Gottardi E; Cilloni D; Bocchia M; Saglio G; Lauria F; Fanin R; Visani G; Marre MC; Maderna M; Rancati F; Vinaccia V; Russo D; Baccarani M. | 2005-01-01 | BLOOD | - | 1.01 Articolo in rivista | - |
| Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases | Malagola M; Peli A; Damiani D; Candoni A; Tiribelli M; Martinelli G; Piccaluga PP; Paolini S; De ...Rosa F; Lauria F; Bocchia M; Gobbi M; Pierri I; Zaccaria A; Zuffa E; Mazza P; Priccolo G; Gugliotta L; Bonini A; Visani G; Skert C; Bergonzi C; Roccaro AM; Filì C; Fanin R; Baccarani M; Russo D. | 2008-01-01 | EUROPEAN JOURNAL OF HAEMATOLOGY | - | 1.01 Articolo in rivista | - |
| INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE | D Russo; G Martinelli; M Malagola; V Cancelli; S Zedda; C Skert; S Soverini; I Iacobucci; D Turri...; S Mirto; M Gobbi; I Pierri1; U Vitolo; P Pregno; M Fogli; N Testoni; A De vivo; F Castagnetti; E Morra; E Pungolino; F Di Raimondo; F Stagno; G Alimena; M Breccia; F Nobile; B Martino; A Rambaldi; T Intermesoli; G Saglio; G Rege Cambrin; G Visani; G Nicolini; P De Fabritiis; E Abruzzese; R Fanin; M Tiribelli ; P Galieni; C Bigazzi; G Specchia; E Angelucci; E Usala; C Musolino; S Ruso; L Gaidano; M Lunghi; F Lauria; M Bocchia; F Rodeghiero; A D’Emilio; A Bosi; V Santini; G Quarta; M Girasoli; G Fioritoni; R Di Lorenzo; B Cesana; G Rosti; M Baccarani. | 2012-01-01 | HAEMATOLOGICA | - | 4.02 Riassunto (Abstract) | - |